Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
ID: 352963Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352963

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-004.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Mar 14, 2024 12:00 AM
  4. 4
    Due Nov 13, 2024 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)". This grant aims to support research focused on identifying and characterizing neuroimmune networks, communication pathways, and targets related to HIV and substance use. The grant also seeks to fund research on the discovery of novel modulatory probes/tools that can enhance our understanding of the regulatory mechanisms underlying neuroimmune interactions in the context of HIV and substance use disorder comorbidity. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is November 13, 2024. For more information and to apply, visit the following link: Research on the Neuro-Immune Axis Grant. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-DA-25-004-Full-Announcement.html
4/10/2024
Similar Opportunities
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)". This grant aims to support research focused on identifying and characterizing neuroimmune networks, communication pathways, and targets related to HIV and substance use. The grant also seeks to fund research on the discovery of novel modulatory probes/tools that can enhance our understanding of the regulatory mechanisms underlying the comorbidity of HIV and substance use disorder. The grant has a funding ceiling of $275,000 and does not require cost sharing or matching. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for applications is November 13, 2024. For more information and to apply, visit the following link: [Research on the Neuro-Immune Axis Grant](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-005.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Targeting Inflammasomes in HIV and Substance Use" under the category of Health. This grant aims to support research that investigates the role of inflammasomes in the neuropathology caused by drug exposure and HIV infection. The objective is to understand how inflammasomes contribute to immune activation and identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations. The research will also focus on identifying novel therapies to target inflammasome activation or suppression for the treatment of neuroinflammation and immune dysregulation. The grant does not require cost sharing or matching requirements and has a maximum award ceiling of $500,000. The eligibility for this grant is open to various entities, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for applications is March 13, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-012.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-012.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)". This grant aims to generate brain region and cell-type specific microglial protein profiles in the context of HIV and SUD. The goal is to establish mechanisms of how HIV-harboring microglia may contribute specifically to neuropathologies encountered with comorbid HIV and SUD. The grant does not require cost sharing or matching. The funding instrument type is a grant and falls under the category of funding activity related to health. The opportunity is discretionary and the CFDA number associated with it is 93.279. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, and more. The closing date for this grant is August 14, 2025. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-014.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-014.html). For any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)". This grant aims to examine the mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control. The research will utilize novel CNS cell systems, organoid models, and single cell technologies. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The opportunity is posted on grants.gov and falls under the discretionary category. The CFDA number associated with this grant is 93.853. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, non-domestic (non-U.S.) entities, regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territories or Possessions, and non-domestic (non-U.S.) components of U.S. Organizations. The closing date for this grant opportunity is November 8, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)". This grant aims to examine the mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control. The research will utilize novel CNS cell systems, organoid models, and single cell technologies. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The opportunity falls under the discretionary category and has a CFDA number of 93.853. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant is November 8, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-181.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-181.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.